Stockreport

Ocugen: A Speculative Buy In Biotech Growing Clinical Trials To Billion-Dollar Revenues [Seeking Alpha]

Ocugen, Inc.  (OCGN) 
PDF Their OCU400 program, targeting inherited eye diseases, is progressing to phase 3 clinical trials in 2024. The company's participation in a $5 billion NIAID-funded tr [Read more]